浅析循证医学指导下的乳腺癌辅助内分泌治疗  

Adjuvant endocrine therapy of breast cancer under the guidance of evidence-based medicine

作　　者：章国晶[1] 谢晓冬[1] Zhang Guo-ring Xie Xiaodong(Oncology Diagnosis and Treatment Center, the General Hospital of Shenyang Military Region, Shenyang 110840, China)

机构地区：[1]沈阳军区总医院全军肿瘤诊治中心,100840

出　　处：《中华内分泌外科杂志》2016年第5期353-355,共3页Chinese Journal of Endocrine Surgery

基　　金：国家十二五重大新药创制平台子课题（2012ZX09303016-002）;辽宁省科技攻关计划课题（2012225019）

摘　　要：辅助内分泌治疗是乳腺癌内分泌治疗中的重要组成部分，本文通过解读相关临床试验、Meta分析、国内外治疗指南及国际著名会议中所涉及的循证医学数据，浅析绝经前辅助内分泌治疗的选择、他莫昔芬辅助内分泌治疗的时限、他莫昔芬序贯芳香化酶抑制剂辅助内分泌治疗的时间截点等几个较有争议的问题。Adjuvant endocrine therapy is an important part of endocrine therapy of breast cancer. Some problems are controversial such as the choice of premenopausal adjuvant endocrine therapy, how long tamoxifen should be taken in adjuvant endocrine therapy, time limit of tamoxifen should be taken before followed by aro- matase inhibitors. The article analyzed data from evidence-based medicine of clinical trials, Meta-analysis, treat- ment guidelines both at home and abroad, international famous conventions to interpret the above problems.

关 键 词：乳腺肿瘤 内分泌治疗 辅助治疗 

分 类 号：R737.9[医药卫生—肿瘤]